BioSpace News Archive

GeoVax Labs, Inc. announced today that the U.S. Department of Defense (DoD) has awarded the Company a $2,442,307 cooperative agreement in supportof its novel Lassa Fever (LF) vaccine development program.

Advanced Bifurcation Systems today announced that the Company has submitted a proposal to the U.S. Federal Drug Administration (“FDA”) for a clinical study leading to an IDE for its bifurcation technology. Concurrently, the Company is defining a regulatory and clinical strategy for Europe to receive a CE mark.

It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.

Here’s a look at who shook things up in the world of pharma and biotech this week.

A study aimed at demonstrating the clinical superiority of THN201 over a standard of care treatment for this severely debilitating symptom

Portfolio of Products, Education and Training to Help Surgeons Handle Challenging Reoperations

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis.

The U.S. Food and Drug Administration approved Pfizer’s once-per-day oral medication Vizimpro, a first-line treatment for patients with a rare form of lung cancer, the company announced late Thursday.

Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).

Just this morning, KSQ Therapeutics disclosed that they’ve obtained an $80 million Series C financing that will be put towards the development of oncology drug candidates via CRISPRomics™, a drug discovery engine that creates insights specific to individual human genes on an industrial scale.